Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts, including four that are late-breaking, will be presented on Epidiolex® (cannabidiol) at the American Epilepsy Society (AES ...
Researchers report that elevated levels of the oral bacteria Fusobacterium nucleatum may be linked with greater disability in ...
Diagnosed with A.L.S., they traded stories, drank tequila and made grim jokes at a unique annual gathering on Cape Cod. Laura McNew-Isaacs had makeup done in advance of a dinner and drag show at the ...
A simple non-invasive hair-based test could one day help with early diagnosis of amyotrophic lateral sclerosis (ALS)—improving patient care and potentially extending survival. This is the hope of ...
Multiple sclerosis (MS) has long been regarded as a disease with different subtypes such as “relapsing” or “progressive.” An international study, published on August 20, 2025, in Nature Medicine under ...
Please provide your email address to receive an email when new articles are posted on . Data from two large U.S. cohorts showed more than 30% of patients with SSc demonstrated an initial symptom other ...
The VEDOSS project has previously shown that 70% of patients with Raynaud's phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on ...
The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on ...
- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback